Overexpression of p53 predicts shorter survival in diffuse type gastric cancer

British Journal of Surgery

Volumn 85, Issue 8, 1998, Pages 1138-1142

  Lee, W J ^a,c   Shun, C T ^a   Hong, R L ^a   Wu, M S ^a   Chang, K J ^a   Chen, K M ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

^c EN CHU KONG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; STOMACH CANCER; SUPPRESSOR GENE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031824277     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00712.x     Document Type: Article

References (38)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-5.
2. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-8.
3. Rodrigues NR, Rowan A, Smith MEF, Kerr IB, Bodmer WF, Gannon JV et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990; 87: 7555-8.
4. Iggo R, Gater K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-9.
5. Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinoma by flow cytometry. Int J Cancer 1990; 45: 450-6.
6. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A et al. Aberrant of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-1703.
7. Lee WC, Lin RS. Interactions between birth cohort and urbanization on gastric cancer mortality in Taiwan. Int J Epidemiol 1994; 23; 252-60.
8. Lee WJ, Lee WC, Houng SJ, Shun CT. Houng RL, Lee PH et al. Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan. World J Surg 1995; 19: 707-13.
9. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis Cancer Res 1991; 51: 3056-8.
10. Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK et al. Occurrence of p53 gene abnormalities in gastric carcinoma tumours and cell lines. J Natl Cancer Inst 1991; 83: 938-43.
11. Matozaki T, Sakamoto C, Suzuki T, Matsuda K, Wada K. Nakano O et al. p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 1992; 52: 4335-42.
12. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amodori D et al. Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993; 53: 2614-17.
13. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukotomi T et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82; 835-40.
14. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA. Hennessy C et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 164: 75-81.
15. Allred DC, Clark GM. Elledge R, Fuqua SA, Brown RW, Chamness GC et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
16. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer lust 1993; 85: 965-70.
17. Kajitani T. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Part II. Histological classification of gastric cancer. Jpn J Surg 1981; 11: 127-45.
18. UICC (International Union Against Cancer). Manaal Harmer P, Sohin LH, eds. TNM Classification of Malignant Tumors. 4th ad. Springer: Berlin, 1987.
19. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31-49.
20. Cox DR. Regression models and life tables. J Roy Slat Soc 1972; 29: 187-220.
21. Seruca R, David L, Holm R, Nesland JM, Fangan BM, Castedo S et al. p53 mutations in gastric carcinomas. Br J Cancer 1992; 65: 708-10.
22. Martin HM, Filipet MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognostic in gastric carcinoma. Int J Cancer 1992; 50: 859-62.
23. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-62.
24. Kakeji Y, Korenaga D, Tsujitani H, Baba H, Anai H, Maehara Y et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993; 67: 589-93.
25. Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP et al. Expression of p53 protein in normal dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol 1993; 170: 279-83.
26. Susano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993; 24: 584-9.
27. Jang WI, Yang WI, Lee CI, Kim HS, Song KS, Cho MY et al. Immunohistochemical detection of p53 protein, c-erbB-2 protein, epidermal growth factor receptor protein and proliferating cell nuclear antigen in gastric carcinoma. J Korean Med Sci 1993; 8: 293-304.
28. Fukunaga M, Monden T, Nakanishi H, Ohue M, Fukuda K, Tomita N et al. Immunohistochemical study of p53 in gastric carcinoma. Am J Clin Pathol 1994; 101: 177-80.
29. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994; 69: 943-6.
30. 1) gastric carcinoma and precancerous adjacent mucosa. Gut 1994; 35: 1697-700.
31. Wright PA, Williams GT. Molecular biology and gastric carcinoma, Gut 1993; 34: 145-7.
32. Tahara E. Molecular biology of gastric cancer. World J Surg 1995; 19: 484-90.
33. Fonseca LH, Yonemura Y, De Aretxabala K, Yamaguchi A, Miwa K. Miyazaki I. p53 detection as a prognostic factor in early gastric cancer. Oncology 1994; 51: 485-90.
34. Motojima K, Furui J, Kohara N, Ito T, Kanematsu T. Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 1994; 116: 890-5.
35. Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K. Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995; 75(Suppl 16): 1454-9.
36. Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA et al. The clinical significance of p53 accumulation in gastric carcinoma. Cancer 1996; 77: 2005-12.
37. Motojima K, Furui J, Kohara N, Izawa K, Kanematsu T, Shiku H. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994; 115: 349-54.
38. Chung YS, Yamashita Y, Kato Y, Nakata B, Sawada T, Sowa M. Prognostic significance of T antigen expression in patients with gastric carcinoma. Cancer 1996; 77: 1768-73.